BIOMARKER:

TSC2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

TSC2 mutation	Peripheral T-cell Lymphoma	TSC2 mutation	Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
TSC2 mutation	Endometrial Cancer	TSC2 mutation	Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 mutation	Renal Cell Carcinoma	TSC2 mutation	Renal Cell Carcinoma	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
TSC2 mutation	Renal Cell Carcinoma	TSC2 mutation	Renal Cell Carcinoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 mutation	Renal Cell Carcinoma	TSC2 mutation	Renal Cell Carcinoma	mTOR inhibitor Sensitive: C3 – Early Trials mTOR inhibitor Sensitive : C3	mTOR inhibitor Sensitive: C3 – Early Trials mTOR inhibitor Sensitive : C3
TSC2 mutation	Pancreatic Cancer	TSC2 mutation	Pancreatic Cancer	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4